×
About 650,322 results

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery
https://www.nejm.org/doi/full/10.1056/NEJMc070348
The New England Journal of Medicine;

Previous studies have demonstrated that IgG and neutralizing antibodies against coronavirus associated with the severe acute respiratory syndrome (SARS) may persist, in spite of a decline in titer, for 2 years in patients who have recovered from SARS.

Update Alert: Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers
https://www.acpjournals.org/doi/10.7326/L20-0768

This is the first monthly update alert for a living review on the epidemiology of and risk factors for coronavirus infections in health care workers (HCWs) (1). Searches were updated from 24 April 2020 to 24 May 2020, using the same search strategies as the original review, and we identified 1125 citations. Applying the same inclusion criteria, we identified 37 additional studies for this updat...

Seasonality of Respiratory Viral Infections
https://www.annualreviews.org/doi/pdf/10.1146/annurev-virology-012420-022445

The seasonal cycle of respiratory viral diseases has been widely recognized for thousands of years, as annual epidemics of the common cold and influenza disease hit the human population like clockwork in the winter season in temperate regions. Moreover, epidemics caused by viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the newly emerging SARS-CoV-2 occur during ...

SARS-CoV-2 and Nervous System - Neurological Manifestations in Patients With COVID-19: A Systematic Review
https://www.neurores.org/index.php/neurores/article/view/602/580

Coronavirus (CoV) is a virus infectious disease with a considerable spectrum of clinical presentations. Symptoms ranged from asymptomatic infection to severe pneumonia that may lead to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and several clinical complications. Neurologic symptoms related to CoV have been described recently in the literature. The relationship between SARS-Co...

Synaptic Plasticity and Levodopa-Induced Dyskinesia: Electrophysiological and Structural Abnormalities
https://pubmed.ncbi.nlm.nih.gov/29492662/
Journal of Neural Transmission;

Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive degeneration of dopaminergic neurons located in the midbrain. The gold-standard therapy for PD is the restoration of dopamine (DA) levels through the chronic administration of the DA precursor levodopa (L-DOPA). Although levodopa therapy is the main therapeutic approach for PD, its use is limited by the develo...

COVID-19 in Immunocompromised Hosts: What We Know So Far
https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa863/5864040
Clinical Infectious Diseases; Monica Fung MD, MPH et. al.

Jun 26th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...

Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
https://link.springer.com/article/10.1007/s00406-019-00982-6
European Archives of Psychiatry and Clinical Neuroscience;

Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is limited in ...

Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283839/
NPJ Parkinson's Disease;

IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson’s disease (PD). The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controll...

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 6th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060863/

The purpose of review is to review the current status of positron emission tomography (PET) molecular imaging of serotonergic system in Parkinson’s patients who experience levodopa-induced (LIDs) and graft-induced dyskinesias (GIDs). PET imaging studies have shown that Parkinson’s disease is characterized by progressive loss of dopaminergic and serotonergic neurons. Parkinson’s patients who exp...

The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure
https://journals.sagepub.com/doi/full/10.1177/2050313X20933473

The COVID-19 pandemic has brought about an urgent need for effective treatment, while conserving vital resources such as intensive care unit beds and ventilators. Antivirals, convalescent plasma, and biologics have been used with mixed results. The profound “cytokine storm” induced endotheliopathy and microthrombotic disease in patients with COVID-19 may lead to acute respiratory distress syndr...

Covid-19: Managing the Surge
https://cssjs.nejm.org/landing-page/covid19response/Covid19Collection.pdf

As Covid-19 spreads around the world, health care leaders and clinicians currently dealing with rising case rates can learn much from those organizations hit with earlier surges of infection. NEJM Catalyst has featured articles, case studies, and conversations since the early days of the pandemic on the many dierent approaches and solutions to the problems posed by the SARS-CoV-2 virus. Th...

Lung ultrasound monitoring in patients with COVID-19 on home isolation
https://www.sciencedirect.com/science/article/pii/S073567572030440X

Many patients with COVID-19, the clinical illness caused by SARS-CoV-2 infection, exhibit mild symptoms and do not require hospitalization. Instead, these patients are often referred for 14-days of home isolation as symptoms resolve. Lung ultrasound is well-established as an important means of evaluating lung pathology in patients in the emergency department and in intensive care units. Ultraso...

Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans
https://www.biorxiv.org/content/10.1101/2020.05.14.095414v1.full.pdf

Several related human coronaviruses (HCoVs) are endemic in the human population, causing mild respiratory infections1 . Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiologic agent of Coronavirus disease 2019 (COVID-19), is a recent zoonotic infection that has quickly reached pandemic spread2,3 . Zoonotic introduction of novel coronaviruses is thought to occur in the ...

Antihypertensive drugs and risk of COVID-19?
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30153-3/fulltext
The Lancet Respiratory Medicine;

Mar 25th, 2020 - Lei Fang and colleagues1 suggest that clinicians should consider withholding angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) because of a potential increased risk of worse clinical outcomes in patients with coronavirus disease 2019 (COVID-19), and they suggest calcium channel blockers as an alternative. The hypothesis behind this suggestion is that the e...

Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection
https://jamanetwork.com/journals/jamacardiology/fullarticle/2770645

Myocarditis is a significant cause of sudden cardiac death in competitive athletes and can occur with normal ventricular function.1 Recent studies have raised concerns of myocardial inflammation after recovery from coronavirus disease 2019 (COVID-19), even in asymptomatic or mildly symptomatic patients.2 Our objective was to investigate the use of cardiac magnetic resonance (CMR) imaging in com...

COVID-19: the older adult and the importance of vitamin D sufficiency
https://www.cambridge.org/core/journals/journal-of-nutritional-science/article/covid19-the-older-adult-and-the-importance-of-vitamin-d-sufficiency/B42BD7C0EE9090DA30B916AF52FD713F

In December 2019, in Wuhan, China, the novel coronavirus ‘severe acute respiratory syndrome 2’ (SARS-CoV-2) was discovered as the cause of a pneumonia-like illness and subsequently named coronavirus disease 2019 (COVID-19). COVID-19 spread and is now a global pandemic. With few exceptions, countries in the Northern hemisphere have higher mortality rates from COVID-19. This may be due to an incr...

Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
https://link.springer.com/article/10.1007/s00702-018-1900-6
Neurology and Preclinical Neurological Studies;

Jul 2nd, 2018 - Symptoms of Parkinson’s disease have been controlled with levodopa for many years; however, motor complications consisting of wearing off of medication effect and dyskinesias tend to occur within a few years of starting levodopa. Motor complications can begin a few months after taking levodopa, with the average time to onset estimated to be 6.5 years. Dyskinesias can be troublesome and require ...

Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003)
https://n.neurology.org/content/88/16_Supplement/S56.003
Neurology

Apr 16th, 2017 - Data from two Phase 3 clinical studies investigating the efficacy and safety of ADS-5102 in Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID) were pooled to summarize results for the shared primary endpoint, Unified Dyskinesia Rating Scale (UDysRS) and its sub-components.

Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600052/
Postgraduate Medical Journal;

Jun 4th, 2007 - Levodopa is the most effective drug for treating Parkinson's disease. However, long‐term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa‐induced dyskinesias (LID). The underlying mechanisms f...